1. Provisional study data by this author suggests Salamol is
both objectively and subjectively less effective than Ventolin (for
publication)
2. This particular PHARMAC decision singly affects more
people than any other previous decisions
3. Estimated Ventolin users affected are 500,000, with
demographics across all age groups from infants to the elderly. The highest
incidence of hospital admissions for asthma is in children less than 5,
followed by children 5-14. Maori and Pacific Island are at higher risk
4. The introduction of the conversion during winter months
would coincide with the peak asthma period
5. Asthma has well recognised psychological
dependency/reassurance factors. People rely on the historical reassurance that
their inhaler will work when they need it. This argument is difficult to
scientifically assess, and is best managed by slow but sure application to
education and promotion
6. To date nearly all consumers and providers do not like
the product. This includes doctors, pharmacists, and consumers
7. The fiscal gains have been reported at $1.7 million over
18 months. On a PHARMAC budget 2004-2005 of $565 million this is 0.2% savings
1. Slow down the roll out to Jan 1 2006
2. Set-up impact studies
3. Put in place special authority arrangements with PHARMAC